New Family of OCT Products and New Eye Care Data Management Software Introduced at Annual Meeting of Ophthalmology

  New Family of OCT Products and New Eye Care Data Management Software
  Introduced at Annual Meeting of Ophthalmology

Carl Zeiss Meditec at the 2012 AAO-APAO Joint Meeting in Chicago

2012 AAO-APAO

Business Wire

CHICAGO & DUBLIN, Calif. & JENA, Germany -- November 17, 2012

Medical technology manufacturer Carl Zeiss Meditec introduced a new family of
OCT products spanning the full spectrum of multi-modality imaging for retinal
disease and glaucoma at the 2012 Joint Meeting of the American Academy of
Ophthalmology (AAO) and the Asia-Pacific Academy of Ophthalmology (APAO) in
Chicago. The company also announced receiving US FDA clearance for Software
Version 3.0 of the FORUM^® Eye Care Data Management System for streamlined
clinical workflow and practice efficiency. Additionally the first 29 subjects
in the US clinical trial for the VisuMax^® ReLEx^® smile procedure have been
treated and the one month results for the first 15 subjects were presented at
a ZEISS sponsored symposium during the Joint Meeting.

Introduction of new family of OCT products

Carl Zeiss Meditec introduced a new family of CIRRUS OCT (Optical Coherence
Tomography) products at the 2012 AAO-APAO Joint Meeting. The new OCT family is
comprised of two CIRRUS™ HD-OCT models, the 5000 and 500, and two integrated
multi-modality OCT and fundus imaging systems, the CIRRUS™ photo 800 and 600.
The new modernized OCT platforms deliver clinical and workflow solutions that
span the spectrum of care and address specific workflow and practice needs.

"The new CIRRUS family offers a choice of high-quality ZEISS OCT clinical
solutions for the diagnosis and management of glaucoma and retinal disease
across all levels of care, from comprehensive practices to advanced
subspecialty practices," says Dr. Ludwin Monz, President and CEO of Carl Zeiss
Meditec AG. "Practitioners can now benefit from diagnostic and workflow
solutions that are tailored specifically for the level of care they provide,
their practice workflow and their case load volumes. The new family of OCT
products enables more practitioners to offer patients a high level of care and
to tailor their investment to their workflow and practice needs."

The CIRRUS HD-OCT 5000 is optimized for high-volume advanced care practices
and is configured with the most sophisticated clinical applications, such as
Advanced RPE Analysis and Ganglion Cell Analysis, and with precise measurement
tools, such as new FastTrac™ retinal tracking, for rapid analysis and
decision-making.

The CIRRUS HD-OCT 500, for comprehensive care practices, offers essential OCT
capabilities with a broad range of clinical applications in an easy-to-learn,
easy-to-use instrument for the management of glaucoma and retinal disease,
retina assessment for cataract surgery, and anterior segment imaging for
corneal disease.

The CIRRUS photo 600 and 800 combine standard-setting CIRRUS OCT technology
with full-featured mydriatic/non-mydriatic fundus imaging into integrated,
compact, multi-modality systems for flexibility and versatility.

The CIRRUS HD-OCT 5000 and 500 are immediately available for sale in the US
and other markets. The CIRRUS photo 800 and 600 are to be released globally in
early 2013.

For more information on the CIRRUS family, please go to:
www.meditec.zeiss.com/press/cirrus-family.

US FDA clearance for software version 3.0 of FORUM Eye Care Data Managment
system

Carl Zeiss Meditec announced receiving US FDA clearance for software version
3.0 for the next version of their FORUM Eye Care Data Management system. FORUM
enables eye care practitioners to centrally store exam data and images from
various instruments – including the new family of CIRRUS HD-OCT and CIRRUS
photo instruments – and to access them quickly and easily at any time. With
the FORUM 3.0 multi-site practices and hospitals can easily and conveniently
interchange data or view exam data from remote sites using the FORUM Viewer.
Preconfigured Clinical Displays accelerate practice workflows through
automatic loading and display of the relevant exam data for various eye
pathologies.

The FORUM Eye Care Data Management system was on display in the ZEISS booth
#534 during the Joint Meeting and was also exhibited at the AAO sponsored IHE
Eye Care Multi-vendor Interoperability Showcase at the Electronic Office.

The latest advancements for CIRRUS HD-OCT and FORUM Eye Care Data Management
was a focus of presentations of leading ophthalmologists at the ZEISS
sponsored symposium “Energize Your Practice with New Diagnostics that
Streamline Patient Care” on Saturday November 10, 2012 at the McCormick Place
West, Conference Center.

For more information go to: www.meditec.zeiss.com/aao.

US Clinical Trial of new Minimally Invasive, All-Femto Laser Vision Correction
Method

Carl Zeiss Meditec announced that the first 29 subjects in the VisuMax IDE
clinical trial in the US have been treated with the ReLEx smile procedure for
the correction of spherical myopia with the VisuMax femtosecond laser. One
month results for the first 15 subjects were presented during the AAO-APAO
Joint Meeting at the ZEISS sponsored symposium “Next Frontier in Perfecting
Corneal Refractive Surgery” by Jon Dishler, MD. Dr. Dishler is the Medical
Monitor for the United States VisuMax clinical trial and the first study site
to initiate treatments using the ReLEx smile procedure. Carl Zeiss Meditec
received conditional approval from the US FDA to initiate the clinical trial
in April 2012.

For more information on the symposium go to: www.meditec.zeiss.com/aao.

Please find more information about the US clinical trial at:
www.meditec.zeiss.com/press/clinical-trial.

Book Launch of Perimetry Primer and Interpretation Guide

Carl Zeiss Meditec and doctors, Anders Heijl, Vincent Michael Patella and Boel
Bengtsson announced the global introduction of “Effective Perimetry –The Field
Analyzer Primer” 4th edition during the 2012 AAO-APAO Joint Meeting.
Introduced nearly 25 years ago, the Humphrey^® primer has become one of the
most consulted perimetry interpretation guides in the world. Meeting attendees
received a free copy of this educational guide. The authors were available for
a complimentary book signing in the ZEISS booth.

For more information: www.meditec.zeiss.com/aao.

Routine Diagnostics Introduction

Rounding off its diagnostic portfolio, Carl Zeiss Meditec introduced the
VISUREF 100, a combination Autorefractor and Keratometer, during the Joint
Meeting. This routine diagnostic instrument is fast, accurate, simple-to-use
and fits easily into a practice's daily routine.

Attendees of the 2012 AAO-APAO Joint Meeting experienced ZEISS‘
state-of-the-art innovations and practice solutions at the ZEISS booth at
McCormick Place South in Chicago.

Brief profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on TecDax of the
German stock exchange, is one of the world’s leading medical technology
companies. The company supplies innovative technologies and
application-oriented solutions designed to help doctors improve the quality of
life of their patients. It provides complete packages of solutions for the
diagnosis and treatment of eye diseases, including implants and consumables.
The company creates innovative visualization solutions in the field of
microsurgery. The medical technology portfolio of Carl Zeiss Meditec is
rounded off by promising, future-oriented technologies such as intraoperative
radiotherapy. In fiscal year 2010/11 (ended 30 September) the company's around
2,400 employees generated revenue of EUR 759 million.

The head office of Carl Zeiss Meditec is in Jena, Germany. The company has
subsidiaries in Germany and abroad; more than 50 percent of its employees are
based in the USA, Japan, Spain and France. The Center for Research and
Development (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center
for Research and Development in Shanghai, China, strengthen the presence in
these rapidly developing economies. 35 percent of Carl Zeiss Meditec shares
are in free float. The remaining 65 percent are held by Carl Zeiss AG, one of
the world’s leading groups in the optical and optoelectronic industries. Carl
Zeiss offers innovative solutions for the future-oriented markets of Medical
and Research Solutions, Industrial Solutions, Eye Care and Lifestyle Products.
Carl Zeiss AG, Oberkochen, is fully owned by the Carl Zeiss Foundation.

For more information, please go to: www.meditec.zeiss.com

Contact:

Contact for the press
Carl Zeiss Meditec AG
Jann Gerrit Ohlendorf, +49 36 41 220-331
Director Corporate Communications
press@meditec.zeiss.com
or
Contact for investors
Carl Zeiss Meditec
Henriette Meyer, Director Investor Relations
www.meditec.zeiss.com/press